Mitoxantrone, Etoposide, Carboplatinum and Ara-C Combination Therapy (Meca) in Refractory and Relapsed Acute Leukemia

References

• Löwenberg B, Downing J R, Burnett A. Acute myeloid leukemia. N Eng J Med 1999; 341: 1051–1062
   PubMed Web of Science ®Google Scholar
• Pui C H, Evans W E. Acute lymphoblastic leukemia. N Ens J Mud 1998; 339: 605–615
   PubMed Web of Science ®Google Scholar
• Forman S J, Schmidt G M, Nademanee A P, Amylon M D, Chao N J, Fahey J L, Konrad P N, Margolin K A, Niland J C, O'Donnell M R, Parker P M, Smith E P, Snyder D S, Somlo G, Stein A S, Blume K G. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol 1991; 9: 1570–1574
   PubMed Web of Science ®Google Scholar
• Biggs J C, Horowitz M M, Gale R P, Ash R C, Atkinson K, Helbig W, Jacobsen N, Phillips G L, Rimm A A, Ringdén O, Roman C, Sobocinski K A, Veum J A, Bortin M M. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992; 80: 1090–1093
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kreutzmann H, Straif K, Ludwig W D, Mertelsmann R, Donhuijsenant R, Lengfelder E, Arlin Z, Büchner D. High-dose cytosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia. Blood 1987; 69: 744–749
   PubMed Web of Science ®Google Scholar
• Walters R S, Kantarjian H M, Keating M J, Plunkett W K, Estey E H, Andersson B, Beran M, McCredie K B, Freireich E J. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 1988; 62: 677–682
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Leblond V, Michallet M, Cordonier C, Fenaux P, Travade P, Dreyfus F, Jaubert J, Devaux Y, Fiere D. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991; 77: 1894–1990
   PubMed Web of Science ®Google Scholar
• Keskin A, Tombuloglu M, Atamer M A, Büyükkeçeci F. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia. Am Haematol 1994; 92: 14–17
   Google Scholar
• Guthrie T H., Jr. High-dose, continuous-infusion cyclo-phosphamide, cytarabine, vincristine, and prednisone for remission inductio in refractory adult acute leukemia. Cancer 1987; 59: 1255–1257
   PubMed Web of Science ®Google Scholar
• Carella A M, Carlier P, Pungolino E, Resegotti Liso L. V, Stasi R, Montillo M, Iacopino P, Mirto S, Pagano L, Leoni F, Martelli F M, Di Raimondo F, Porcelli A, De Riu L, Nosari A M, Cimino R, Damasio E, Miraglia E, Fioritoni G, Ricciuti Carotenuto F. M, Longinotti M, Defazio D, Fazi P, Mandelli F., for the GIMEMA Cooperative Group. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 1993; 7: 196–199
   PubMed Web of Science ®Google Scholar
• Martino R, Brunet S, Sureda A, Guardia R, Aventin A, Soler J, Altés A, Domingo-Albós A. Hematopoietic Growth Factor (G-CSF or GM-CSF) after salvage chemotherapy in refractory or relapsed adult de novo acute leukemia. Leukemia and Lymphoma 1996; 20: 321–326
   PubMed Web of Science ®Google Scholar
• Kornblau S M, Kantarjian H, O'Brian S, Andreeff M, Koller C A, Beran M, Keating M, Estey E. CECA-cyclophos-phamide, etoposide, carboplatin and cytosine arabinoside. A new salvage regimen for relapsed or refractory acute myelogenous leukemia. Leukemia and Lymphoma 1998; 28: 371–375
   PubMed Web of Science ®Google Scholar
• Mayers F J, Welborn J, Lewis J P, Flynn N. Infusion carboplatin treatment of relapsed and refractory acute leukemia: Evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol 1989; 7: 173–178
   PubMed Web of Science ®Google Scholar
• Martínez J A, Martin G, Sanz G F, Sempere A, Jarque I, de la Rubia J, Sanz M A. A phase II clinical trial of carboplatin infusion in high-risk acute non-lymphoblastic leukemia. J Clin Oncol 1991; 9: 39–43
   PubMed Web of Science ®Google Scholar
• Vogler W R. High-dose carboplatin in the treatment of hematologic malignancies. Oncology 1993; 50(Supp1. 2)42–46
   PubMed Web of Science ®Google Scholar
• Santana V, Mirro J, Kearns C, Schell M J, Crom W, Blakley R L. 2-Chloroadeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992; 10: 364–370
   PubMed Web of Science ®Google Scholar
• Parker J E, Pagliuca A, Cullis J O, Czepulkowski B, Rassam S M, Samaratunga I R, Grace R, Cover P A, Mufti G J. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997; 99: 939–944
   PubMed Web of Science ®Google Scholar
• Bassan R, Lerede T, Buelli M, Boleri G, Bellavita P, Ram-Baldi A, Barbui T. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia. Haematologica 1998; 83: 422–427
   PubMed Web of Science ®Google Scholar
• Kanarjian H M, Estey E H, Keating M A. New chemo-therapeutic agents in acute myeloid leukemia. Leukemia; Suppl 1996; 1: S4–S6
   Google Scholar
• List A E, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. A phase MI trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652–1660
   PubMed Web of Science ®Google Scholar
• Bennet J M, Catovsky D, Daniel M T, Fladrin G, Galton D AG, Gralnick H R, Sultan C. Proposal for the classification of acute leukemia. Br J Haematol 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Miller A B, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Vaughan W P, Karp J E, Burke P J. Long chemotherapy-free remissions after single-cycle timed sequential chemotherapy for acute myelocytic leukemia. Cancer 1980; 45: 850–865
   Web of Science ®Google Scholar
• Amadori S, Arcese W, Isacchi G, Meloni G, Petti M C, Monarca B, Testi A M, Mandelli F. Mitoxantrone, etoposide, and intermediate-dose cytarabine: An effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991; 9: 1210–1214
   PubMed Web of Science ®Google Scholar
• Kern W, Aul C, Maschmeyer G, Kuse R, Kerkhoff Grote-Metke A, Eimermacher H, Kubica U, Wörmann B, Büchner Hiddemann T, for the German AML Cooperative Group. Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. Ann Hematol 1998; 77: 115–121
   PubMed Web of Science ®Google Scholar
• Bassan R, Chiodini B, Zucchetti M, Lerede T, Cornelli P E, Cortelazzo S, Barbui T. Short course infusion idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results. Haematologica 1998; 83: 27–33
   PubMed Web of Science ®Google Scholar
• Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gratti A M, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M. High efficacy of fludarabine-containing therapy (LANG-RANG) in poor risk acute myeloid leukemia. Haematologica 1996; 81: 513–520
   PubMed Web of Science ®Google Scholar
• Kern W, Schleyer E, Underhalt M, Wörmann B, Büchner T, Hiddemann W. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Cancer 1997; 79: 59–68
   PubMed Web of Science ®Google Scholar